natgillin/translations-raw huggingface dataset:
Persistence of antibody response (postdose 3) has been observed for 10 years in adolescents who were 9-15 years of age at time of vaccination; 9 years in women, 16-23 years of age at time of vaccination; 6 years in men, 16-26 years of age at time of vaccination, and 8 years in women, 24-45 years of age at time of vaccination.
Opaženo je da odgovor protutijela (nakon 3. doze) traje 10 godina u adolescenata koji su u vrijeme cijepljenja bili u dobi od 9 do 15 godina; 9 godina u žena koje su u vrijeme cijepljenja bile u dobi od 16 do 23 godine; 6 godina u muškaraca koji su u vrijeme cijepljenja bili u dobi od 16 do 26 godina i 8 godina u žena koje su u vrijeme cijepljenja bile u dobi od 24 do 45 godina.
Persistence of immune response
Postojanost imunološkog odgovora
Persistence of immune response and booster response in children 2 to 10 years of age
Postojanost imunološkog odgovora i odgovora nakon docjepljivanja u djece u dobi od 2 do 10 godina
Persistence of immune response in adolescents aged 11-17 years of age
Postojanost imunološkog odgovora u adolescenata u dobi od 11-17 godina
Persistence of immune response in adolescents and adults aged 11-25 years
Postojanost imunološkog odgovora u adolescenata i odraslih u dobi od 11-25 godina
Persistence of immune response in children aged 2-10 years
Postojanost imunološkog odgovora u djece u dobi od 2-10 godina
Persistence of immune response in children aged 6-10 years
Postojanost imunološkog odgovora u djece u dobi od 6-10 godina
Persistence of resistance–associated substitutions
Ustrajnost supstitucija povezanih s rezistencijom
Persistence of ZOSTAVAX efficacy was studied 4 to 7 years postvaccination in the STPS, which included 7,320 subjects previously vaccinated with ZOSTAVAX and 6,950 subjects previously vaccinated with placebo in the SPS (mean age at enrollment was 73.3 years); and 7 to 10 years postvaccination in the Long-term Persistence Substudy (LTPS), which included 6,867 subjects previously vaccinated with ZOSTAVAX (mean age at enrollment into the LTPS was 74.5 years).
Trajnost djelotvornosti cjepiva ZOSTAVAX bila je ispitana 4 do 7 godina nakon cijepljenja u podispitivanju STPS, koje je uključilo 7320 ispitanika prethodno cijepljenih cjepivom ZOSTAVAX i 6950 ispitanika prethodno cijepljenih placebom u ispitivanju SPS (srednja dob pri uključenju bila je 73,3 godine); i 7 do 10 godina nakon cijepljenja u Podispitivanju dugotrajne zaštite (LTPS), koje je uključilo 6867 ispitanika prethodno cijepljenih cjepivom ZOSTAVAX (srednja dob pri uključenju u ispitivanje LTPS bila je 74,5 godina).
persistent crying lasting 3 hours or more within 48 hours of vaccination
ako je neprekidno plakalo 3 sata ili dulje unutar 48 sati nakon cijepljenja
Persistent dermal overdosing of imiquimod cream could result in severe local skin reactions.
Učestalo dermalno predoziranje imikvimod kremom može dovesti do ozbiljnih lokalnih kožnih reakcija.
Persistent diarrhoea or colitis should be managed with corticosteroids at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents.
Ako proljev ili kolitis potraju, treba ih zbrinuti kortikosteroidima u dozi od 0,5 do 1 mg/kg/dan ekvivalenata metilprednizolona.
Persistent elevations in these laboratory values should be managed with corticosteroids at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents.
Ako povišenja tih laboratorijskih vrijednosti potraju, treba ih zbrinuti kortikosteroidima u dozi od 0,5 do 1 mg/kg/dan ekvivalenata metilprednizolona.
persistent eye pain and inflammation (if prolonged) new pain, weakness or discomfort in your thigh, hip or groin.
bol u oku ili upala oka koji ne prestaju (ako traju dulje) novonastala bol, slabost ili nelagoda u bedru, kuku ili preponama.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
bol u oku i upala oka koja ne prolazi nova bol, slabost ili neugoda u bedru, kuku ili preponama.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
bol u oku i upala oka koji ne prestaju novonastala bol, slabost ili nelagoda u bedru, kuku ili preponama.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
bol u oku ili upala oka koji ne prestaju novonastala bol, slabost ili nelagoda u bedru, kuku ili preponama.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
talna bol u oku ili upala bol, slabost ili neugoda u bedru, kuku ili preponama.
persistent for > 4 weeks, or
perzistentan > od 4 tjedna, ili
persistent for ≥ 4 weeks, or
perzistentan – traje duže od 4 tjedna, ili
Persistent grade 2 (longer than 7 days)
Perzistirajući 2. stupanj (dulje od sedam dana)
Persistent hyperglycaemia greater than
Perzistentna hiperglikemija veća od
Persistent infection that lasts for at least 6 months has also been shown to be a relevant surrogate marker for cervical cancer.
Perzistentna infekcija koja je trajala bar 6 mjeseci također se pokazala kao relevantni klinički surogat markera za karcinom cerviksa.
Persistent muscle weakness or muscle pain (myopathy/myositis), muscle cramp
trajna mišićna slabost ili bol u mišićima (miopatija/miozitis), grč mišića
persistent numbness, tingling or pain in feet and/or hands (this may indicate the beginning of peripheral neuropathy, an adverse effect on the nerves), muscular weakness
trajna utrnulost, trnci ili bol u stopalima i/ili rukama (ovo može upućivati na početak periferne neuropatije, nuspojave koja zahvaća živce), mišićna slabost
Persistent or extreme sleepiness
Trajna ili ekstremna pospanost
persistent or recurrent ischemic cardiac pain marked ECG changes (in particular ST-segment abnormalities) raised cardiac enzymes or markers (e.g.
perzistentna ili ponavljajuća ishemična bol u predjelu srca izražene promjene EKG-a (osobito poremećaji ST-segmenta) povišeni srčani enzimi ili markeri (npr.
persistent pain and/or non-healing of sores in the mouth or jaw (osteonecrosis of the jaw),
trajna bol i/ili nezarastanje rana u ustima ili čeljusti (osteonekroza čeljusti),
Persistent Pulmonary Hypertension in the Newborn (PPHN)
Perzistentna plućna hipertenzija novorođenčeta (PPHN)
Persistent worsening of Functional Class due to PH
uporno pogoršavanje funkcionalnog razreda zbog PH
persistent, inconsolable crying lasting 3 hours or more, occurring within 48 hours of vaccination.
uporni, neutješni plač koji traje 3 sata ili više, nastao unutar 48 sati od cijepljenja
Persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination;
Uporni, neutješni plač koji traje ≥ 3 sata, nastao unutar 48 sati od cijepljenja;
Persistent, inconsolable crying lasting  3 hours, occurring within 48 hours of vaccination;
Trajan, neutješan plač u trajanju  3 sata, koji se javlja unutar 48 sati nakon cijepljenja;
Persistently infected immunotolerant piglets represent a very high risk since they are shedding field virus and they cannot be identified serologically due to their seronegative status.
Trajno inficirana imunotolerantna prasad predstavlja vrlo visoki rizik jer izlučuju terenski virus, a ona se ne mogu serološki identificirati zbog svog seronegativnog statusa.
Persistently infected immunotolerant piglets represent a very high risk since they are shedding field virus and they cannot be identified serologically due to their seronegative status.
Trajno inficirana imunotolerantna prasad predstavlja vrlo visoki rizik jer izlučuju virulentni virus, a oni se ne mogu serološki identificirati zbog svog seronegativnog statusa.
Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed creatine phosphokinase (CK) elevation above 5 times the ULN under previous statin treatment (see section 4.4).
Osobna anamneza miopatije i/ili rabdomiolize sa statinima i/ili fibratima, ili potvrđeno povišenje kreatinin-fosfokinaze (CK) u serumu 5 puta iznad GGN tijekom prethodnog liječenja statinom (vidjeti dio 4.4).
Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous statin treatment (see section 4.4)
Miopatija i/ili rabdomioliza sa statinima i/ili fibratima ili potvrđeno povišenje kreatin-fosfokinaze preko 5 puta iznad gornje granice normale (GGN) pri prethodnom liječenju statinom u osobnoj anamnezi (vidjeti dio 4.4)
Personal or familial history of hereditary muscular disorders
Nasljedni mišićni poremećaji u osobnoj ili obiteljskoj anamnezi
Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product and cleaning the measuring device.
Treba koristiti osobnu zaštitnu opremu koja sadrži zaštitne rukavice dok rukujete s veterinarsko medicinskim proizvodom i čistite mjerne uređaje.
Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product.
Pribor za osobnu zaštitu koji se sastoji od rukavica treba koristiti pri rukovanju veterinarsko- medicinskim proizvodom.
Personal protective equipment consisting of gloves when handling broken or damaged syringes.
Pribor za osobnu zaštitu koji se sastoji od rukavica treba koristiti pri rukovanju slomljenim ili oštećenim štrcaljkama.
Personal protective equipment consisting of impervious gloves and a half-mask respirator conforming to European Standard EN 149 or a non- disposable respirator conforming to European Standard EN 140, with a filter conforming to European Standard EN 143 should be worn when mixing the product.
Kada se miješa veterinarsko-medicinski proizvod ili rukuje ljekovitom hranom za životinje, potrebno je nositi opremu za osobnu zaštitu koja se sastoji od zaštitnog odijela, nepropusnih rukavica te ili zaštitne polumaske za disanje za jednokratnu primjenu u skladu s europskim standardom EN 149 ili naprave za disanje za višekratnu primjenu u skladu s europskim standardom EN 140, s filterom prema europskom standardu EN 143.
Personal protective equipment consisting of protective disposable gloves and safety glasses should be worn when handling the veterinary medicinal product.
Pribor za osobnu zaštitu koji se sastoji od zaštitnih jednokratnih rukavica i sigurnosnih naočala treba koristiti pri rukovanju s veterinarsko-medicinskim proizvodom.
Personal relationships
Međuljudski odnosi
Personnel handling this medicinal product during dilution should wear protective clothing including mask, goggles and gloves.
Osoblje koje rukuje lijekom tijekom pripreme lijeka mora nositi zaštitnu odjeću koja uključuje masku, zaštitne naočale i rukavice.
Personnel handling this medicinal product during handling/transfer should wear protective clothing including mask, goggles and gloves.
Osobe koje rukuju ovim lijekom prilikom rukovanja/prijenosa trebale bi nositi zaštitnu odjeću uključujući masku, zaštitne naočale i rukavice.
Personnel handling this medicinal product during handling/transfer should wear protective clothing including mask, goggles and gloves.
Osoblje koje rukuje ovim lijekom mora prilikom rukovanja/prenošenja ovoga lijeka nositi zaštitnu odjeću, što uključuje i zaštitnu masku, zaštitne naočale i zaštitne rukavice.
Personnel handling this medicinal product during reconstitution should wear protective clothing including masks, goggles and gloves.
Djelatnici koji rukuju ovim lijekom tijekom rekonstitucije trebaju nositi zaštitnu odjeću uključujući maske, zaštitne naočale i rukavice.
Personnel handling this medicinal product should wear protective clothing including mask, goggles and gloves.
Osoblje koje rukuje ovim lijekom mora nositi zaštitnu odjeću koja uključuje masku, zaštitne naočale i rukavice.
Personnel handling this medicine during reconstitution should wear protective clothing including mask, goggles and gloves
osoblje koje rukuje ovim lijekom tijekom rekonstitucije treba nositi zaštitnu odjeću, uključujući masku, naočale i rukavice
personnel must wear protective clothing: goggles, gowns, disposable gloves and masks; a designated area should be defined for preparation (preferably under a laminar flow system).
osoblje mora nositi zaštitnu odjeću: zaštitne naočale, ogrtače, jednokratne rukavice i maske; potrebno je odrediti posebno mjesto za pripremu (poželjno pod sustavom laminarnog protoka).
personnel should be trained in good technique for handling anticancer agents;
osoblje treba obučiti kako ispravno rukovati agensima za liječenje neoplazmi;
Personnel should be trained to prepare and administer the medicinal product.
Osoblje mora biti osposobljeno za pripremu i primjenu lijeka.
Personnel should be trained to reconstitute the medicinal product.
Djelatnike treba obučiti rekonstituciji lijeka.
Personnel should be trained to reconstitute the medicinal product.
Osoblje mora biti educirano za rekonstituciju lijeka.
Personnel should be trained to reconstitute the medicine
osoblje treba proći obuku za rekonstituciju lijeka
Persons above 60 years should start with a dose of 0.1–0.2 mg per day which should be slowly increased according to individual requirements.
Osobe starije od 60 godina trebaju započeti dozom od 0,1–0,2 mg na dan, koju treba polako povećavati sukladno potrebama pojedine osobe.
Persons administering the product:
Osobe koje primjenjuju proizvod:
Persons aged 18-65 years can be vaccinated in a rapid schedule as follows: First dose at Day 0.
Osobe u dobi od 18 - 65 godina mogu primiti cjepivo prema brzom rasporedu kako slijedi: Prva doza na nulti (0.) dan.
Persons not previously vaccinated with Prepandrix
Osobe koje nisu ranije primile cjepivo Prepandrix
Persons previously vaccinated with one or two doses of Prepandrix containing HA derived from a different clade of the same influenza subtype as the pandemic influenza virus:
Osobe koje su ranije cijepljene s jednom ili dvije doze cjepiva Prepandrix koje sadrži hemaglutinine (HA) dobivene iz različitih linija istog podtipa influence kao virus pandemijske influence:
Persons who have allergic reactions to injected IGF-1, who have unexpectedly high blood values of IGF-1 after injection, or who fail to show a growth response may be having an antibody response to injected IGF-1.
Bolesnici koji imaju alergijske reakcije na injicirani IGF-1, koji imaju neočekivano visoke vrijednosti IGF-1 u krvi nakon injiciranja, ili kod kojih ne dolazi do rasta možda stvaraju antitijela na IGF-1.
Persons with known hypersensitivity to the active substance or any of the excipients should administer the product with caution.
Osobe preosjetljive na djelatnu tvar ili na bilo koju od pomoćnih tvari trebaju oprezno primijenjivati proizvod.
Persons ≥ 653
Osobe ≥ 65 godina3
Pertactin (PRN) 3 micrograms
Pertaktin (PRN) 3 mikrograma
Pertactin (PRN)1 8 micrograms
Pertaktin (PRN)1 8 mikrograma
Pertactin1 8 micrograms
Pertaktin1 8 mikrograma
Pertussis (often called whooping cough) is a highly infectious illness that affects the airways.
Hripavac (često zvan magareći kašalj) je visoko zarazna bakterijska infekcija koja zahvaća dišne putove.
Pertussis (often called whooping cough): a highly infectious illness that affects the airways.
Hripavac (često zvan magareći kašalj): vrlo zarazna bolest koja napada dišne puteve.
pertussis (whooping cough);
hripavca (magarećeg kašlja);
pertussis (whooping cough);
hripavca (velikog kašlja);
Pertussis response rates were similar to the control vaccine for all pertussis antigens after the booster dose.
Stope odgovora za pertusis bile su slične s kontrolnim cjepivom za sve antigene pertusisa nakon doze docjepljivanja.
Pertussis Toxoid (PT) 20 micrograms
Toksoid hripavca (PT) 20 mikrograma
Pertussis toxoid (PT)1 25 micrograms
Toksoid pertusisa (PT)1 25 mikrograma
Pertussis Toxoid 25 micrograms
Toksoid hripavca (PT) 25 mikrograma
Pertussis Toxoid 25 micrograms
Toksoid hripavca 25 mikrograma
Pertussis toxoid, adsorbed 25 micrograms
toksoid pertusisa1, adsorbiran 25 mikrograma
Pertussis toxoid1 25 micrograms
Toksoid pertusisa1 25 mikrograma
Pertuzumab exposure was reported in offspring from all treated groups, at levels of 29% to 40% of maternal serum levels at GD100.
Izloženost pertuzumabu prijavljena je u mladunčadi iz svih ispitivanih skupina, i to u razinama od 29% do 40% koncentracije lijeka u serumu majke na 100. dan gestacije.
Pertuzumab has been designed to recognise and attach to HER2, a protein found on the surface of HER2-positive cancer cells.
Pertuzumab je dizajniran kako bi prepoznao i vezao se na HER2, protein koji se nalazi na površini stanica raka pozitivnih na HER2.
Pertuzumab is a humanised IgG1 monoclonal antibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA technology.
Pertuzumab je humanizirano IgG1 monoklonsko protutijelo proizvedeno u kulturi stanica sisavaca (stanice jajnika kineskog hrčka) tehnologijom rekombinantne DNK.
Pertuzumab may elicit severe diarrhoea.
Pertuzumab može izazvati težak proljev.
Peru,
Peru, vojska
Peru, Pampas
Pampas
PET (polyethylene terephthalate) vial of 20 ml closed with a nitryl-based rubber stopper and sealed with an aluminium cap.
PET (polietilen tereftalat) bočica od 20 ml zatvorena nitrilnim gumenim čepom i zabrtvljena aluminijskim poklopcem.
PET (polyethylene terephthalate) vials of 20, 50, 100, 200 or 500 ml, closed with nitrile rubber stoppers and sealed with aluminium caps.
PET ( polietilen tereftalat ) bočice od 20, 50, 100, 200 i 500 ml zatvorenih s nitril gumenim čepom i zapečaćene s aluminijskom kapicom.
PET bottle containing 50 ml or 100 ml closed with a bromobutyl rubber stopper and sealed with an aluminium tear-off cap.
PET bočica od 50 ili 100 ml zatvorene zatvorena čepom od bromobutil-gume i zabrtvljene aluminijskom tear-off kapicom.
PET bottle polypropylene measuring syringe
PET boca polipropilen mjerenje šprice
PET bottle, aluminium or white plastic screw cap
PET bočica, aluminijski ili bijeli plastični čep
PET Net Muenchen GmbH - MUNICH Marchioninistrasse 15
PET Net Muenchen GmbH- MUNICH Marchioninistrasse 15
PET Net Muenchen GmbH, Germany
PET Net Muenchen GmbH, Njemačka
PET studies in humans and preclinical data suggest that TMZ crosses rapidly the blood-brain barrier and is present in the CSF.
Ispitivanja u ljudi primjenom PET-a kao i neklinički podaci pokazuju da TMZ brzo prelazi krvno- moždanu barijeru i da je prisutan u cerebrospinalnom likvoru.
PET studies in humans and preclinical data suggest that TMZ crosses rapidly the blood-brain barrier and is present in the CSF.
Ispitivanja u ljudi primjenom PET-a kao i neklinički podaci pokazuju na to da TMZ brzo prelazi krvno-moždanu barijeru i da je prisutan u cerebrospinalnom likvoru.
PET studies in humans and preclinical data suggest that TMZ crosses rapidly, the blood-brain barrier and is present in the CSF.
Ispitivanja u ljudi primjenom PET-a kao i neklinički podaci pokazuju na to da TMZ brzo prelazi krvno-moždanu barijeru i da je prisutan u cerebrospinalnom likvoru.
PET studies in humans and preclinical data suggest that TMZ crosses the blood-brain barrier rapidly and is present in the CSF.
Ispitivanja u ljudi primjenom PET-a kao i neklinički podaci ukazuju na to da TMZ brzo prelazi krvno- moždanu barijeru i da je prisutan u cerebrospinalnom likvoru.
PET vial (50 ml): Store in a refrigerator (2 C – 8 C).
PET bočice (50 ml): Čuvati u hladnjaku (2C – 8C).
PET vial in a cardboard box
PET bočica u kartonskoj kutiji
PET vials (10 ml, 50 ml) and glass vials (2 ml, 10 ml, 50 ml)
PET ampule (10 ml, 50 ml) i staklene ampule (2 ml, 10 ml, 50 ml)
PET vials of 20, 50, 100, 200 and 250 ml.
PET bočice: 20, 50, 100, 200 i 250 ml.
PET vials: 20 ml Polyethylene terephthalate (PET) vials, clear
PET bočice: 20 ml polietilen tereftalat (PET) bočice, prozirne, 50 ml PET bočice, prozirne,
PET vials: 20 ml Polyethylene terephthalate (PET) vials, clear 50 ml PET vials, clear
PET bočice: 20 ml polietilen tereftalat (PET) bočice, prozirne, 50 ml PET bočice, prozirne,
PET-bottles with polypropylene child-resistant closure containing 50, 150 or 480 ml per bottle.
PET boce s polipropilenskim sigurnosnim zatvaračem za djecu koje sadrže 50, 150 ili 480 ml po boci.
Petechiae
petehije
Petechiae**
petehije
Petechiae***
Petehije
Petechiae,
petehije,
petechiae, pruritus (includes generalized), rash, ecchymosis
petehije, svrbež (uključuje generalizirani), osip, ekhimoze
Petechiae; Alopecia; Drug eruption; Dermatitis^
petehije; alopecija; izbijanje koţnih promjena uzrokovano lijekom; dermatitis^
Pethidine
Petidin
pethidine or propoxyphene - used for pain
petidin ili propoksifen - koriste se za ublažavanje boli
pethidine, piroxicam, propoxyphene (used to relieve pain);
petidin, piroksikam, propoksifen (koriste se za ublažavanje boli);
Pethidine, piroxicam, propoxyphene Ritonavir co-administration is likely to result in increased plasma concentrations of pethidine, piroxicam, and propoxyphene and is therefore contraindicated (see section 4.3).
Petidin, piroksikam, propoksifen Istodobno primijenjeni ritonavir vjerojatno bi povećao plazmatske koncentracije petidina, piroksikama i propoksifena te je stoga kontraindiciran (vidjeti dio 4.3).
PETNET Solutions Northwood, HA6 2RN, United Kingdom
PETNET Solutions Northwood, HA6 2RN, Velika Britanija
PETNET Solutions Northwood, HA6 2RN, United Kingdom
PETNET Solutions, Northwood, HA6 2RN, Velika Britanija
PETNET Solutions, 91090, Lisses, France
PETNET Solutions 91090, Lisses, Francuska
PETNET Solutions, 91090, Lisses, France
PETNET Solutions, 91090 Lisses, Francuska
PETNET Solutions, Nottingham, NG5 1PB, United Kingdom
PETNET Solutions, Nottingham, NG5 1PB, Velika Britanija
PETNET Solutions, Nottingham, NG5 1PB, United Kingdom
PETNET Solutions, Nottingham, NG51PB, Velika Britanija
Peutz-Jeghers syndrome (a disorder that causes blockage of the bowel and where your hands, soles of your feet and surface of your lips may have brown freckles)
Peutz-Jeghersov sindrom (poremećaj koji uzrokuje začepljenje crijeva, s pojavom smeđih pjega na rukama, stopalima i na površini usana)
Pexion 100 mg tablets for dogs Pexion 400 mg tablets for dogs Imepitoin
Pexion 100 mg tablete za pse Pexion 400 mg tablete za pse Imepitoin
Peyona 20 mg/ml solution for infusion and oral solution caffeine citrate
Peyona 20 mg/ml otopina za infuziju i oralna otopina kofeincitrat
Peyona can be either used without dilution or diluted in sterile solutions for infusion such as glucose 50 mg/ml (5%) or sodium chloride 9 mg/ml (0.9%) or calcium gluconate 100 mg/ml (10%) immediately after withdrawal from the ampoule.
Peyona se može primijeniti bez razrjeđivanja ili razrijediti u sterilnoj otopini za infuziju, kao što je 5% otopina glukoze (50 mg/ml), 0,9% otopina natrijevog klorida (9 mg/ml) ili 10% otopina kalcijevog glukonata (100 mg/ml) odmah nakon izvlačenja iz ampule.
Peyona should only be used in a neonatal intensive care unit in which adequate facilities are available for patient surveillance and monitoring.
Peyona se smije primjenjivati samo u jedinici neonatalne intenzivne skrbi u kojoj je dostupna prikladna oprema za nadzor i praćenje bolesnika.
Peyona will be infused by controlled intravenous infusion, using a syringe infusion pump or other metered infusion device.
Peyona će se davati kontroliranom intravenskom infuzijom pomoću infuzijske pumpe za štrcaljku ili druge infuzijske naprave s mjernim mehanizmom.
Peyona1 caffeine citrate
Peyona1 kofeincitrat
Peyronie's disease
Peyronijeva bolest
Peyronie’s disease
Peyronijeva bolest
Peyronie’s disease is a condition in which men develop plaques of fibrous, scar-like tissue in their penis, causing it to become abnormally curved, and sometimes leading to pain or difficulty in sexual intercourse.
Peyronijeva bolest je stanje u kojem se u muškaraca razvijaju plakovi fibroze, tkiva sličnog ožiljcima u penisu, što uzrokuje abnormalnu zakrivljenost, a ponekad uzrokuje bol ili poteškoće tijekom spolnog odnosa.
Peyronie’s disease occurs exclusively in adult male patients and hence there is no relevant information for use in females.
Peyronijeva bolest javlja se isključivo u odraslih muških bolesnika i zato nema relevantnih informacija za primjenu u žena.